Catalent has been granted a patent for antibodies specific to Mucin 1, useful in treating cell proliferative disorders by enhancing immune responses. The patent also covers nucleic acids, cells, and compositions related to the antibodies, along with diagnostic and monitoring applications. GlobalData’s report on Catalent gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Catalent Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Catalent, was a key innovation area identified from patents. Catalent's grant share as of April 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

Antibodies binding to mucin-1 for therapeutic and diagnostic use

Source: United States Patent and Trademark Office (USPTO). Credit: Catalent Inc

A recently granted patent (Publication Number: US11970546B2) discloses an antibody or its fragment specifically binding to Mucin-1 (MUC-1). The antibody comprises specific amino acid sequences in both heavy and light chains, as detailed in the patent claims. The patent covers various configurations of the antibody, including those meeting Kabat, Chothia, and IMGT definitions, providing a detailed framework for the development of antibodies targeting MUC-1.

Furthermore, the patent extends to pharmaceutical compositions containing the described antibody or fragment thereof, along with a pharmaceutically acceptable carrier. The compositions may also include a T cell activator, encapsulation in liposomes, or immobilization on solid supports. The patent also encompasses modifications to the antibody, such as the addition of a contrast agent or a covalently linked lipid moiety. Overall, the patent offers a comprehensive guide for the development and application of antibodies targeting MUC-1, potentially opening new avenues in the field of targeted therapy and diagnostics.

To know more about GlobalData’s detailed insights on Catalent, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies